Comparative Pharmacology
Head-to-head clinical analysis: PENICILLIN 2 versus V CILLIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PENICILLIN 2 versus V CILLIN.
PENICILLIN-2 vs V-CILLIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting transpeptidase activity, and activating autolytic enzymes.
Penicillin G (V-CILLIN) inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting transpeptidase activity and autolysin activation, leading to cell lysis.
250 mg orally every 6 hours or 500 mg orally every 8 hours for mild to moderate infections; intravenous dosing: 1-2 million units every 4-6 hours.
250-500 mg orally every 8 hours or 500 mg every 12 hours for mild to moderate infections.
None Documented
None Documented
30-60 minutes; prolonged in renal impairment (up to 10 hours in anuria)
Terminal elimination half-life ~30-60 minutes in normal renal function; prolonged in renal impairment (up to 10 hours in anuria).
Renal: 60-80% unchanged; biliary/fecal: minor (10-20%)
Primarily renal (60-70% unchanged via tubular secretion); minor biliary/fecal elimination (<10%).
Category C
Category C
Penicillin Antibiotic
Penicillin Antibiotic